Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints
NCT00296894
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Erosive Osteo-Arthritis
Interventions
DRUG:
Adalimumab (40 mg sc every other week)
DRUG:
Placebo
Sponsor
University Hospital, Ghent